Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
12.63
-1.14 (-8.28%)
Sep 1, 2026, 4:00 PM EDT - Market closed
Kazia Therapeutics Revenue
In the fiscal year ending June 30, 2025, Kazia Therapeutics had annual revenue of 27.47K AUD, down -98.22%.
Revenue (ttm)
27.47K AUD
Revenue Growth
-98.22%
P/S Ratio
113.96
Revenue / Employee
4,578 AUD
Employees
6
Market Cap
144.32M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 27.47K | -1.51M | -98.22% |
| Jun 30, 2024 | 1.54M | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | 11.38M | - | - |
| Jun 30, 2020 | - | - | - |
| Jun 30, 2019 | - | - | - |
| Jun 30, 2018 | 88.14K | -103.61K | -54.04% |
| Jun 30, 2017 | 191.74K | -110.71K | -36.60% |
| Jun 30, 2016 | 302.46K | 233.93K | 341.39% |
| Jun 30, 2015 | 68.52K | -13.54K | -16.50% |
| Jun 30, 2014 | 82.06K | -934.10K | -91.92% |
| Jun 30, 2013 | 1.02M | -462.73K | -31.29% |
| Jun 30, 2012 | 1.48M | -692.41K | -31.89% |
| Jun 30, 2011 | 2.17M | 660.44K | 43.71% |
| Jun 30, 2010 | 1.51M | -515.17K | -25.43% |
| Jun 30, 2009 | 2.03M | -10.72M | -84.10% |
| Jun 30, 2008 | 12.74M | -1.94M | -13.23% |
| Jun 30, 2007 | 14.69M | 1.73M | 13.35% |
| Jun 30, 2006 | 12.96M | -273.67K | -2.07% |
| Jun 30, 2005 | 13.23M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| LENZ Therapeutics | 21.48M |
| Equillium | 4.39M |
| NRx Pharmaceuticals | 3.39M |
| Connect Biopharma Holdings | 2.95M |
| Milestone Pharmaceuticals | 2.34M |
| Humacyte | 2.12M |
| Outlook Therapeutics | -1.16M |
KZIA News
- 21 hours ago - Kazia Therapeutics price target raised to $40 from $34 at BTIG - TheFly
- 23 hours ago - Kazia Therapeutics announces new preclinical, translational data on paxalisib - TheFly
- 23 hours ago - Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy - PRNewsWire
- 23 hours ago - Kazia Therapeutics expands paxalisib trial into HR+/HER2- breast cancer - TheFly
- 1 day ago - Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer - PRNewsWire
- 1 day ago - Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering - PRNewsWire
- 4 days ago - Kazia Therapeutics 2.58M share Spot Secondary priced at $15.50 - TheFly
- 4 days ago - Kazia Therapeutics announces pricing of $120M public offering - TheFly